<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Reports of Biochemistry and Molecular Biology</title>
<title_fa></title_fa>
<short_title>rbmb.net</short_title>
<subject>Basic Sciences</subject>
<web_url>http://rbmb.net</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-3480</journal_id_issn>
<journal_id_issn_online>2322-3480</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/rbmb</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1399</year>
	<month>2</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2020</year>
	<month>5</month>
	<day>1</day>
</pubdate>
<volume>9</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review</title>
	<subject_fa>زیست شناسی ملکولی</subject_fa>
	<subject>Molecular Biology</subject>
	<content_type_fa>مقالات مروری</content_type_fa>
	<content_type>Review</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;&lt;em&gt;Background:&lt;/em&gt;&lt;/strong&gt; Since its first appearance in December of 2019, regular updates around the world demonstrates that the number of new Corona Virus 2019 (COVID-19) cases are increasing rapidly, indicating that not only does COVID-19 exhibit a rapid spread pattern, but human intervention is necessary for its resolution. Up until today (27-5-2020) and according to the World Health Organization (WHO), the number of confirmed COVID-19 cases has surpassed 4.5 million with more than 307, 500 deaths. Almost all countries have been affected by COVID-19, and resultingly, various drug trials have been conducted, however, a targeted treatment remains to be made accessible to the public. Recently, Angiotensin-Converting Enzyme-2 &lt;strong&gt;(&lt;/strong&gt;ACE2) has gained some attention for its discovery as a potential attachment target of COVID-19.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Methods:&lt;/em&gt;&lt;/strong&gt; We reviewed the most recent evidence regarding ACE2 distribution and action, the binding mechanism of COVID-19 and its correlation to cellular injury, ACE2 polymorphisms and its association to fatal COVID-19 and susceptibility and, finally, current ACE2-based pharmacotherapies against COVID-19.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/strong&gt; Blocking the ACE2 receptor-binding domain (RBD) using a specific ligand can prevent COVID-19 from binding, and consequently cellular entry and injury. Comparatively, soluble ACE2, which has a higher affinity to COVID-19, can neutralize COVID-19 without affecting the homeostatic function of naturally occurring ACE2. Lastly, ACE2 mutations and their possible effect on the binding activity of COVID-19 may enable researchers to identify high-risk groups before they become exposed to COVID-19.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Conclusions:&lt;/em&gt;&lt;/strong&gt; ACE2 represents a promising target to attenuate or prevent COVID-19 associated cellular injury.&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>ACE, ACE2, COVID-19.</keyword>
	<start_page>97</start_page>
	<end_page>105</end_page>
	<web_url>http://rbmb.net/browse.php?a_code=A-10-502-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Gomaa</first_name>
	<middle_name></middle_name>
	<last_name>Mostafa-Hedeab</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>gomaa_hedeab@yahoo.com</email>
	<code>100319475328460017544</code>
	<orcid>100319475328460017544</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Pharmacology department, Medical College, Jouf University, KSA. &amp; Pharmacology department, Faculty of Medicine, Beni-Suef University, Egypt.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
